What is Aperiam Bio?
Founded in 2020 and headquartered in Brooklyn, New York, Aperiam Bio is a pioneering company focused on developing advanced protein and pulmonary products. The company distinguishes itself by creating stronger, faster proteins and is the sole entity employing a 3D computer vision algorithm to enhance protein functionality beyond natural capabilities. This innovative approach positions Aperiam Bio at the forefront of biopharmaceutical advancements.
How much funding has Aperiam Bio raised?
Aperiam Bio has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2023): $9M with participation from KdT Ventures, Civilization Ventures, and Axial Worldwide
Key Investors in Aperiam Bio
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials. They often provide the first institutional check into companies, leading or co-leading pre-seed and seed funding rounds.
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions. Since its inception in 2017, the firm has managed over $200 million in capital and partnered with more than 70 companies.
Axial Worldwide
Axial Worldwide Corporation is a website design and development company based in Navi Mumbai, specializing in website design, development, eCommerce solutions, SEO, and social media optimization. The company focuses on delivering innovative and results-driven web-based solutions tailored to meet the needs of corporate clients.
What's next for Aperiam Bio?
The recent major enterprise-level funding suggests Aperiam Bio is poised for significant scaling and further research and development. This strategic investment will likely accelerate the company's efforts to bring its enhanced protein technologies to market, potentially expanding its therapeutic applications and solidifying its position in the competitive biotech landscape. Future growth may involve clinical trials, strategic partnerships, and broader commercialization efforts.
See full Aperiam Bio company page
